XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...

Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The biotechnology sector is expanding quickly due to rising demand for ...